Pc.6 Acupressure for Dental Nausea: A Preliminary Report of a Prospective Randomised Double Blind Clinical Trial, Part 1

1997 ◽  
Vol 15 (1) ◽  
pp. 6-9 ◽  
Author(s):  
RAC Chate
Keyword(s):  
First Trimester ◽  
Small Sample ◽  
Cytotoxic Agents ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
First Trimester Of Pregnancy ◽  
The Difference ◽  
Prior Application ◽  
Randomised Controlled

Acupressure effectively reduces the amount of nausea experienced, both in the first trimester of pregnancy, and after either opiates or cytotoxic agents. The aim of this randomised, controlled study was to establish whether it could also reduce any sensation of nausea related to the taking of maxillary dental impressions. The sample comprised 8 males and 14 females, with a mean age of 14.64 years and whose self-registration of nausea following an impression was greater than 33% of a 100mm visual analogue. The test involved a second impression with prior application of pressure on either PC.6, the sixth point on the Chinese pericardial meridian, or a placebo point on the forearm of the patient's dominant limb. A random mental choice as to which point to press was made by each patient, and double blind conditions prevailed. After the withdrawal of the impression, another visual analogue was marked. Of the 9 patients who had used the placebo point during the test impression, there had been a mean reduction of 29% in the scale of nausea experienced. Of the 13 who had used the PC.6 acupressure point, the mean reduction was 30%. The difference was not significant. Three and a half minutes of acupressure on PC.6 did not reduce the sensation of nausea induced by tactile stimulation of the soft palate in this small sample of susceptible patients.

Pc.6 Acupressure for Dental Nausea: A Prospective Randomised Double Blind Clinical Trial with Crossover, Part 2

1998 ◽  
Vol 16 (2) ◽  
pp. 69-72 ◽  
Author(s):  
RAC Chate
Keyword(s):  
Clinical Trial ◽  
Selection Criterion ◽  
Initial Point ◽  
First Trimester ◽  
Small Sample ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
The Mean ◽  
The Difference ◽  
Prior Application

This reports the second part of a single-centre, prospective, randomised, double-blind clinical trial with crossover. It has aimed to assess whether PC.6 acupressure could reduce nausea related to maxillary dental impression taking. The selection criterion was a self registration of nausea greater than 33% of a 100mm visual analogue scale (VAS) following an initial maxillary impression (control) in patients referred for treatment. Exclusion criteria were: current medication with a secondary emetic or anti-emetic effect, prior knowledge of PC.6 acupressure, a recent history of nausea, and the first trimester of pregnancy. Twenty three entered the trial and 18 completed. The test involved a second and third impression with prior application of finger pressure on either PC.6 or a dummy point on the forearm The initial point was chosen by the patient, leaving the other point to be pressed subsequent to crossover. The mean level of nausea was recorded by patients after PC.6 acupressure and also after pressure at a dummy point. These recordings were then compared. The sample consisted of 6 males and 12 females, and the mean age was 14.74 years. The mean difference in nausea between PC.6 acupressure and pressure at the dummy point was −0.39mm % of the VAS (SD 40.48mm %). The 95% Confidence Interval was −20.52 and 19.74mm %, and the difference was not significant. Three and a half minutes of PC.6 acupressure did not significantly reduce nausea experienced with a maxillary impression, compared with pressure at the dummy point, in this small sample: both showed a mean reduction of 50% on the control figure.

scholarly journals A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer

Gut ◽  
1998 ◽  
Vol 42 (1) ◽  
pp. 17-19 ◽  
Author(s):  
J N Primrose ◽  
G V Miller ◽  
S R Preston ◽  
J Gokhale ◽  
N S Ambrose ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Placebo Group ◽  
Median Survival ◽  
Palliative Resection ◽  
Controlled Study ◽  
Double Blind ◽  
Randomised Controlled Study ◽  
Tumour Group ◽  
The Difference ◽  
Randomised Controlled

Background—Does the use of the histamine H2 receptor antagonist ranitidine improve the outcome of patients with gastric cancer?Patients—A total of 222 patients with gastric cancer who had received radical or palliative resection or who were deemed inoperable at presentation.Setting—Hospitals within Yorkshire, the participating clinicians being members of the Yorkshire GI Tumour Group.Methods—A multicentre prospective randomised double blind trial comparing ranitidine 150 mg twice daily with placebo twice daily was undertaken. The principal outcome measures were survival and survival excluding those who died within 30 days of operation.Results—The median survival (95% confidence intervals) was 331 (232 to 393) days for patients in the ranitidine group compared with 187 (143 to 269) for those in the placebo group. The difference in survival was not statistically significant (p = 0.225). When patients who died within 30 days of operation were excluded (21 in the placebo group, 15 in the ranitidine group), the difference in survival remained not significant (p = 0.358). No subgroup could be identified who significantly benefited from treatment, but for patients with stage VIa cancer the median survival was 134 days with placebo compared with 313 days with ranitidine (p = 0.073).Conclusion—This study does not show significant benefit from the use of ranitidine for gastric cancer but further larger studies may be indicated.

FRACTIONAL DETERMINATIONS OF URINARY 17-KETOSTEROIDS IN HYPEREMESIS GRAVIDARUM

1962 ◽  
Vol 41 (1) ◽  
pp. 123-128 ◽  
Author(s):  
Pentti A. Järvinen ◽  
Sykkö Pesonen ◽  
Pirkko Väänänen
Keyword(s):  
Hyperemesis Gravidarum ◽  
First Trimester ◽  
Control Group ◽  
Before And After ◽  
Daily Urine ◽  
First Trimester Of Pregnancy ◽  
The Difference

ABSTRACT The fractional determination of 17-ketosteroids in the daily urine was performed in nine cases of hyperemesis gravidarum and in four control cases, in the first trimester of pregnancy both before and after corticotrophin administration. The excretion of total 17-KS is similar in the two groups. Only in the hyperemesis group does the excretion of total 17-KS increase significantly after corticotrophin administration. The fractional determination reveals no difference between the two groups of patients with regard to the values of the fractions U (unidentified 17-KS), A (androsterone) and Rest (11-oxygenated 17-KS). The excretion of dehydroepiandrosterone is significantly higher in the hyperemesis group than in the control group. The excretion of androstanolone seems to be lower in the hyperemesis group than in the control group, but the difference is not statistically significant. The differences in the correlation between dehydroepiandrosterone and androstanolone in the two groups is significant. The high excretion of dehydroepiandrosterone and low excretion of androstanolone in cases of hyperemesis gravidarum is a sign of adrenal dysfunction.

Omega-3 as an adjunctive therapy of sertraline and venlafaxine substantially improves symptoms of major depressive disorder: A double-blind, placebo-controlled study

2021 ◽  
Vol 10 ◽  
Author(s):  
Mohammad Ahadifard Moghaddam ◽  
Malihe Farid ◽  
Mahboobeh Mehrabani Natanzi ◽  
Zohre Khodaii ◽  
Rahim Badrfam ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Controlled Study ◽  
P Value ◽  
Omega 3 ◽  
Major Depressive ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Severity Of Depression

Background: Due to the possible effect of omega-3 fatty acids on reducing depressive symptoms, in this study, we investigated these effects in combination with other antidepressants. Methods: The study was a double-blind clinical trial on 100 patients with major depressive disorder who were divided into four groups of 25 each and treated with 50 mg daily sertraline plus placebo, 50 mg daily sertraline plus two grams Omega 3 daily, 75 mg daily venlafaxine plus placebo, and 75 mg daily venlafaxine plus 2 g Omega 3 daily for 6 weeks. Results: The mean Hamilton depression rating score of sertraline and venlafaxine plus omega-3 after treatment were 4.42 and 4.23 respectively versus sertraline and venlafaxine plus placebo 14.4 and 14.2 respectively (P value=0.0001). Conclusion: Omega-3 enhanced the clinical function of sertraline and venlafaxine to reduce the severity of depression. Adding omega-3 to either sertraline or venlafaxine does not have a comparative advantage over each other in terms of the improvement of severity of depressive symptoms. Trial registration : number is IRCT20190302042885N1.

Continuous bilateral thoracic paravertebral blockade for analgesia after cardiac surgery: a randomised, controlled trial

Perfusion ◽  
2017 ◽  
Vol 32 (7) ◽  
pp. 591-597 ◽  
Author(s):  
Geoff G. Lockwood ◽  
Leilani Cabreros ◽  
Dorota Banach ◽  
Prakash P. Punjabi
Keyword(s):  
Cardiac Surgery ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Morphine Consumption ◽  
Controlled Study ◽  
Double Blind ◽  
Clinical Trial Registration ◽  
Subcutaneous Infusion ◽  
Randomised Controlled Study ◽  
Randomised Controlled

Background: Continuous bilateral thoracic paravertebral blockade has been used for analgesia after cardiac surgery, but its efficacy has never been formally tested. Method: Fifty adult patients were enrolled in a double-blind, randomised, controlled study of continuous bilateral thoracic paravertebral infusion of 0.5% lidocaine (1 mg.kg-1.hr-1) for analgesia after coronary surgery. Control patients received a subcutaneous infusion of lidocaine at the same rate through catheters inserted at the same locations as the study group. The primary outcome was morphine consumption at 48 hours using patient-controlled analgesia (PCA). Secondary outcomes included pain, respiratory function, nausea and vomiting. Serum lidocaine concentrations were measured on the first two post-operative days. Results: There was no difference in morphine consumption or in any other outcome measure between the groups. Serum lidocaine concentrations increased during the study, with a maximum of 5.9 mg.l-1. There were no adverse events as a consequence of the study. Conclusion: Bilateral paravertebral infusion of lidocaine confers no advantage over systemic lidocaine infusion after cardiac surgery. Clinical trial registration: ISRCTN13424423 ( https://www.isrctn.com )

scholarly journals Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and Semi-Double Blind Controlled Study

2017 ◽  
Vol 2 (20;2) ◽  
pp. 27-35
Author(s):  
PyungBok Lee
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
College Teaching ◽  
Small Sample ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
High Concentration ◽  
Double Blind ◽  
Peripheral Neuropathic Pain ◽  
Topical Capsaicin

Background: Topical capsaicin therapy may be of benefit in providing pain relief in patients with peripheral neuropathy. Objectives: To investigate the efficacy and safety of 0.625% (50 µg/cm2 ) and 1.25% (100 µg/cm2 ) capsaicin patches (CPs) compared to conventional 0.075% capsaicin cream or placebo patches in patients suffering from peripheral neuropathy. Study Design: Early Phase II, multi-center, randomized, semi-double-blind, and placebocontrolled clinical trial. Setting: Two medical college teaching hospitals. Methods: Sixty patients were randomized to the 0.625% CP, 1.25% CP, placebo-controlled patch, or 0.075% capsaicin cream. The primary efficacy endpoint was the mean difference in the change of daily numerical rating scale (NRS) pain score. Secondary endpoints included values for the Daily Sleep Interference Scale, the percentage of patients achieving a ≥ 30% or ≥ 50% reduction in pain, and data for Global Impression Change (GIC) and EQ-5D. Results: Patients treated with the 0.625% CP and 0.075% capsaicin cream showed statistically significant improvements in pain after 6-weeks of test drug application. Daily sleep disorder scores were improved only for those patients applying the 0.075% capsaicin cream. For patient-derived GIC scores, the majority (11 of 12) of patients in the 0.625% CP group reported that their pain was improved. For the safety evaluation, 2 severe adverse events were reported for the 0.075% capsaicin cream group only. Repetitive patch application was related to minor skin problems such as a burning sensation, erythema, pruritus, and vesicles in 28 patients (46.67%). Limitations: The small sample size and relatively high dropout rates. Conclusion: Our data indicate that the 0.625% CP may prove to be an effective and safe alternative with which to treat patients with peripheral neuropathy and could replace the high concentration (8%) CP. Further studies are now needed to definitively establish efficacy. Key words: Capsaicin, patch, CP, topical capsaicin, neuropathic pain, peripheral neuropathic pain, PNP, high concentration CP

A randomized clinical efficacy study targeting mPGES1 or EP4 in dogs with spontaneous osteoarthritis

2019 ◽  
Vol 11 (516) ◽  
pp. eaaw9993
Author(s):  
Carol Robertson-Plouch ◽  
John R. Stille ◽  
Peng Liu ◽  
Claire Smith ◽  
Dorothy Brown ◽  
...  
Keyword(s):  
Posterior Probability ◽  
Brief Pain Inventory ◽  
Repeated Measure ◽  
Controlled Study ◽  
Prostaglandin E ◽  
Double Blind ◽  
Mixed Effect ◽  
Secondary Endpoints ◽  
Efficacy Measures ◽  
The Difference

Canine studies of spontaneous osteoarthritis (OA) pain add valuable data supporting drug treatment mechanisms that may translate to humans. A multicenter, randomized, double-blind, placebo- and active-controlled study was conducted in client-owned dogs with moderate OA pain to evaluate efficacy of LYA, an inhibitor of microsomal prostaglandin E synthase-1 (mPGES1), an EP4 antagonist (LYB), and carprofen, versus placebo. Of 255 dogs screened, 163 were randomized (placebo/LYA/LYB/carprofen: n = 43/39/42/39) and 158 completed treatment. Efficacy versus placebo was assessed using Bayesian mixed-effect model for repeated measure analyses of the Canine Brief Pain Inventory (CBPI) pain interference score (PIS; primary endpoint), pain severity score, and overall impression, as well as the Liverpool Osteoarthritis in Dogs (LOAD) mobility score. The posterior probability that the difference to placebo was <0 at week 2 was 80% for LYA and 54% for LYB for CBPI PIS (both <95% predefined threshold). For secondary endpoints, the posterior probability that the difference to placebo was <0 at week 2 ranged from 89 to 96% for LYA and from 56 to 89% for LYB. The posterior probabilities comparing carprofen to placebo groups were ≥90% for all efficacy endpoints. The proportion of dogs with one or more adverse event was not significantly different from placebo (32.6%) for LYA (35.9%) or carprofen (25.6%), but the rate for LYB (59.5%) was higher versus placebo (P = 0.017). LYA treatment demonstrated consistent improvement in all efficacy measures, suggesting that inhibition of mPGES1 may be an effective treatment for chronic pain associated with OA.

scholarly journals Beta alanine supplementation effects on metabolic contribution and swimming performance

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Matheus Silva Norberto ◽  
Ricardo Augusto Barbieri ◽  
Danilo Rodrigues Bertucci ◽  
Ronaldo Bucken Gobbi ◽  
Eduardo Zapaterra Campos ◽  
...  
Keyword(s):  
Repeated Measures ◽  
Energy Demand ◽  
Swimming Performance ◽  
Controlled Study ◽  
Double Blind ◽  
Repeated Measures Anova ◽  
Beta Alanine ◽  
Before And After ◽  
The Difference ◽  
And Performance

Abstract Background Investigations of β-alanine supplementation shows effects on metabolic (aerobic and anaerobic) participation and performance on swimming by a possible blood acidosis buffering. Considering this background, the objective of the present study was to analyze the effects of β-alanine supplementation on metabolic contribution and performance during 400-m swim. Methods Thirteen competitive swimmers underwent a 6-week, double-blind placebo-controlled study, ingesting 4.8 g.day− 1 of β-alanine or placebo. Before and after the supplementation period, the total anaerobic contribution (TAn) and 30-s all-out tethered swimming effort (30TS) were assessed. Anaerobic alactic (AnAl) and lactic energy (AnLa) was assumed as the fast component of excess post-exercise oxygen consumption and net blood lactate accumulation during exercise (∆[La−]), respectively. Aerobic contribution (Aer) was determined by the difference between total energy demand and TAn. In addition to conventional statistical analysis (Repeated measures ANOVA; p > 0.05), a Bayesian repeated measures ANOVA was used to evidence the effect probability (BFincl). Results No differences and effects were found between groups, indicating no supplementation effects. Repeated measures ANOVA, with confirmation of effect, was indicate reduce in ∆Lactate (p: 0.001; BFincl: 25.02); absolute AnLa (p: 0.002; BFincl: 12.61), fatigue index (p > 0.001; BFincl: 63.25) and total anaerobic participation (p: 0.008; BFincl: 4.89). Conclusions Thus, the results demonstrated that all changes presented were evidenced as a result of exposure to the training period and β-alanine supplementation doesn’t affect metabolic contribution and performance during 400-m freestyle.

Sign in / Sign up

Export Citation Format

Share Document